No Data
No Data
Analysts Expect Breakeven For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Before Long
We feel now is a pretty good time to analyse Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) business as it appears the company may be on the cusp of a considerable accomplishment. Iovance Biotherapeu
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and deliver
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Iovance Biotherapeutics (IOVA) and Intellia Therapeutics (NTLA)
Express News | Iovance Biotherapeutics Inc : Truist Securities Cuts Target Price to $25 From $26
Truist Adjusts Iovance Biotherapeutics' Price Target to $25 From $26, Keeps Buy Rating
Iovance Biotherapeutics (IOVA) has an average rating of buy and price targets ranging from $19 to $34, according to analysts polled by Capital IQ. Price: 10.85, Change: -0.12, Percent Change: -1.09
Express News | HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $32 Price Target
No Data
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long